GEN Exclusives

More »

GEN News Highlights

More »
Apr 15, 2008

Aileron Obtains $10M to Further Peptide Drugs Targeting Intracellular Protein-Protein Interactions

  • Aileron Therapeutics raised $10 million through a private placement of preferred stock. The firm plans to use these proceeds to expand its drug discovery team and open a 10,000 sq. ft. research facility in Cambridge, MA. Apple Tree Partners and the Novartis Venture Fund co-led the round.

    Aileron is developing peptide therapeutics directed at intracellular protein-protein interaction targets that, according to the firm, are not addressable by current drug modalities. Its cell-penetrating Stapled Peptide technology is being applied to generate compounds for the treatment of cancer and other diseases.

    “Aileron is entering an exciting new stage of development now that it has commenced full-fledged internal drug discovery operations in Cambridge with a world-class team of scientists and a very committed group of investors,” says Joseph A. Yanchik III, CEO.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »